揭示酶抑制剂难以捉摸的抗疟疾作用方式
Jessica L Home1, Christopher D Goodman1
1School of BioSciences, University of Melbourne, VIC, 3010, Australia.
Trends in parasitology
|August 20, 2025
概括
一个重新设计的人类激酶抑制剂显示出对疟疾的高疗效,具有最小的交叉抵抗. 然而,确切的药物目标和作用机制仍然不清楚,这说明了识别药物目标的挑战.
科学领域:
- 疟疾学 疟疾学
- 药物发现 药物发现 药物发现
- 寄生虫学的寄生虫学
背景情况:
- 抗疟疾药物耐药性需要新的治疗策略.
- 重用药物为临床应用提供了更快的途径.
- 识别药物点对于理解作用机制至关重要.
研究的目的:
- 评估重新使用的人类激酶抑制剂作为一种新型抗疟疾药物.
- 调查潜在的药物标和抑制剂的作用机制.
- 评估与现有抗疟疾药物的交叉耐药性概况.
主要方法:
- 在体外抗疟疾活性测定.
- 对抗耐药性等菌株的交叉耐药性研究.
- 蛋白质和基因分析以确定药物点.
- 生物化学测定用于研究酶抑制.
主要成果:
- 激酶抑制剂显示出强大的抗疟疾活性.
- 与已确定的抗疟药物观察到最小的交叉耐药性.
- 建议将等离子体酶和血红蛋白消化作为潜在的目标.
- 确切的作用模式仍未确定.
结论:
- 重用酶抑制剂是抗疟疾药物开发的有希望的途径.
- 尽管有希望的疗效,但药物标的模糊性强调了标识的挑战.
- 需要进一步的研究来阐明优化抗疟疾疗法的确切作用机制.
相关概念视频
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Principles of Drug Action
6.6K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
6.6K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
256
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
256
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.2K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.2K


